A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

Muro, Kei; Kim, Tae Won; Park, Young Suk; Uetake, Hiroyuki; Nishina, Tomohiro; Nozawa, Hiroaki; Matsumoto, Hiroshi; Yamazaki, Kentaro; Han, Sae-Won; Lee, Keun-Wook; Deng, Yanhong; Buyse, Marc E.; Satoh, Taroh; Ryoo, Baek-Yeol; Shen, Lin; Iwasa, Satoru; Morita, Satoshi; Sakamoto, Junichi; Xu, Rui-hua

doi:10.1200/jco.2016.34.4_suppl.tps780

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

作者：Muro, Kei; Kim, Tae Won; Park, Young Suk; Uetake, Hiroyuki; Nishina, Tomohiro; Nozawa, Hiroaki; Matsumoto, Hiroshi; Yamazaki, Kentaro; Han, Sae-Won; Lee, Keun-Wook; Deng, Yanhong; Buyse, Marc E.; Satoh, Taroh; Ryoo, Baek-Yeol; Shen, Lin; Iwasa, Satoru; Morita, Satoshi; Sakamoto, Junichi; Xu, Rui-hua

来源：Gastrointestinal Cancers Symposium, San Francisco, CA, 2016-01-21 To 2016-01-23.

DOI：10.1200/jco.2016.34.4_suppl.tps780